Introduction {#s1}
============

Congenital long-QT syndrome (LQTS) is an inherited cardiac disorder characterized by the prolongation of ventricular repolarization, susceptibility to Torsades de Pointes (TdP), and a risk for sudden death ([@B1]). Various types of congenital LQTS exist, but the most common forms of LQTS, accounting for ≈90% of genotype-positive LQTS cases ([@B2]), are LQT1, LQT2, and LQT3, caused by mutations in the genes encoding the pore-forming α-subunits of the ion channels carrying the slow delayed rectifier K^+^ current (I~Ks~), rapid delayed rectifier K^+^ current (I~Kr~), and fast Na^+^ current (I~Na~), respectively \[for reviews, see ([@B3], [@B4]) and, more recent, ([@B5], [@B6])\]. The incidence and occurrence of phenotype is modulated by a large number of conditional factors ([@B4]), including heart rate (HR) ([@B7]). For example, LQT1 patients are found to be at greatest risk for cardiac events during conditions of elevated HR, while slower HR provokes cardiac events in LQT2 and LQT3 patients ([@B7]). Modulation of HR by exercise may also be a diagnostic criterion in LQTS ([@B8]), and treatment/prevention of cardiac events in LQTS is frequently accomplished by HR control ([@B7], [@B9]).

Interestingly, almost all of the ion channels affected by the various types of LQTS gene mutations are also expressed in the human sinoatrial node (SAN) ([@B10]). It is therefore not surprising that LQTS is frequently associated with a change in basal HR due to impaired SAN pacemaker activity ([@B11]). For example, bradycardia is frequently observed in LQT1 mutation carriers, especially in the fetal-neonatal period ([@B12], [@B13]). It has even been concluded that sinus bradycardia in the cardiotocogram may indicate LQTS in the fetus ([@B14]) and that fetal bradycardia is an important predictor of LQTS ([@B15]). Also, basal HR was found to be significantly slower in patients with LQT1 compared with non-carriers ([@B16]). Maximum HR during exercise may also be reduced in LQTS \[see ([@B8], [@B11]), and primary references cited therein\]. Thus, LQTS may have a direct impact on HR ([@B17]), but this is not a consistent finding ([@B18], [@B19]). One may argue that this is because effects on HR differ between types of LQTS and between specific mutations. However, even within a single mutation different effects on HR are described. For example, the A341V mutation in *KCNQ1* may result in sinus bradycardia ([@B13]), but may also occur in absence of baseline HR changes compared to non-carriers ([@B19]).

Because LQTS-related rhythm disorders can be triggered by slow or high HR and sinus pauses ([@B4], [@B11]), detailed knowledge of the relation between LQTS and SAN function is required. In this mini-review, we provide an overview of known LQTS mutations with effects on HR and the underlying changes in expression and kinetics of mutant channels.

LQTS gene mutations and changes in basal heart rate {#s2}
===================================================

In Tables [S1](#SM1){ref-type="supplementary-material"}--[S8](#SM1){ref-type="supplementary-material"}, which are part of our Supplementary Material, we provide a detailed overview of the various autosomal dominant LQTS mutations known to date that are associated with sinus bradycardia, together with data on the mutation-induced changes in expression and kinetics of the respective ion channels. Below, we provide a brief overview of the various types of congenital LQTS and the extent to which each type is associated with sinus bradycardia. This overview is accompanied by Table [1](#T1){ref-type="table"}, which summarizes the data of Tables [S1](#SM1){ref-type="supplementary-material"}--[S8](#SM1){ref-type="supplementary-material"}.

###### 

Mutations observed in patients with both sinus bradycardia and LQTS[^a^](#TN1){ref-type="table-fn"}.

  **LQTS type**   **Gene**    **Protein**      **Patient groups**         **Mutations**
  --------------- ----------- ---------------- -------------------------- -------------------------------------------------------------------------------------------------
  LQT1            *KCNQ1*     K~V~7.1          Single patient             c.387-5 T\>A, R174H, L175fsX, G179S, G325R, S338F, F339S, F339del, A344V, K422fsX, T587M, A590T
                                               Multiple single patients   R231C, A341V, D611Y
  LQT2            *KCNH2*     K~V~11.1         Single patient             R534C, A561V
                                               Small family               K638del
  LQT3            *SCN5A*     Na~V~1.5         Small family               QKP1507--1509del
                                               Large family               1795insD
                                               Multiple families          KPQ1505--1507del (ΔKPQ), E1784K
  LQT4            *ANK2*      Ankyrin-B        Single patient             I1855R
                                               Multiple single patients   R1788W
                                               Multiple families          E1425G
  LQT5            *KCNE1*     KCNE1 (minK)     Single patient             A8V, D85N, R98W
                                               Multiple single patients   D85N
                                               Small family               D85N
  LQT6            *KCNE2*     KCNE2 (MirP1)    Multiple single patients   M54T
  LQT7            *KCNJ2*     Kir2.1           --                         --
  LQT8            *CACNA1C*   Ca~V~1.2         Single patient             A582D, P857R, R858H
  LQT9            *CAV3*      Caveolin-3       Multiple single patients   T78M
  LQT10           *SCN4B*     Na~V~β4          Single patient             L179F
  LQT11           *AKAP9*     Yotiao           --                         --
  LQT12           *SNTA1*     α1-syntrophin    --                         --
  LQT13           *KCNJ5*     Kir3.4 (GIRK4)   --                         --
  LQT14           *CALM1*     Calmodulin       Single patient             E105A
                                               Multiple single patients   F142L
  LQT15           *CALM2*     Calmodulin       Single patient             D96V, N98I, D132H
  LQT16           *CALM3*     Calmodulin       Single patient             D96H, F142L

*Further details are provided in Tables [S1](#SM1){ref-type="supplementary-material"}--[S8](#SM1){ref-type="supplementary-material"}, which are part of our Supplementary Material*.

LQT1
----

LQT1 is due to loss-of-function mutations in *KCNQ1*, the gene encoding the pore-forming α-subunit of the I~Ks~ channel (K~V~7.1). A decrease in I~Ks~ will result in a prolongation of the ventricular action potential (AP) and a prolongation of the QT interval on the ECG ([@B20]). Of note, four K~V~7.1 α-subunits assemble in a tetramer to create the pore of an I~Ks~ channel. Therefore, a mutation in *KCNQ1* may affect a large majority of the I~Ks~ channels as wild-type and mutant subunits co-assemble in heterotetramers.

Many *KCNQ1* mutations exist and some are associated with sinus bradycardia (Table [1](#T1){ref-type="table"}). These bradycardia-associated mutations result in "loss-of-function" by a reduced level of channel expression, expression of non-functional channels, activation at more positive membrane potentials, faster deactivation kinetics, and/or inhibited cAMP-dependent stimulation. For example, the A341V mutation strongly suppresses the increase in I~Ks~ in response to cAMP ([@B21]), which may also explain the more pronounced phenotype during exercise. Sinus bradycardia in LQT1 patients seems limited to isolated, often neonate cases (Table [S1](#SM1){ref-type="supplementary-material"}).

It is somewhat difficult to envision how a loss of repolarizing I~Ks~ *per se* would lead to a profound increase in the cycle length of SAN cells, thus generating sinus bradycardia. Such loss would lengthen AP duration (APD), but at the same time shorten the considerably longer ([@B22]) diastolic phase by increasing the rate of diastolic depolarization. An increase in repolarizing I~Ks~, on the other hand, as observed in short QT syndrome type 2 (SQT2), will inhibit diastolic depolarization and substantially increase cycle length, despite an accompanying decrease in APD, as observed in simulations by Fabbri et al. ([@B23]) using their recently developed comprehensive computer model of a single human SAN pacemaker cell. Clinically, sinus bradycardia is indeed relatively common in SQT2 patients \[see, e.g., ([@B24])\].

LQT2
----

LQT2 is due to loss-of-function mutations in *KCNH2*, the gene encoding the pore-forming α-subunit of the I~Kr~ channel (K~V~11.1). Observation of sinus bradycardia in LQT2 patients seems rare ([@B25], [@B26]) and limited to a few isolated cases and a small family (Table [1](#T1){ref-type="table"}). Bradycardia does occur in the fetal-neonatal period, but is due to 2:1 atrioventricular block rather than sinus bradycardia ([@B12]). Such cases are not included in Table [1](#T1){ref-type="table"}. In contrast, Horigome et al. ([@B13]) reported that the incidence of sinus bradycardia was comparable between groups of young (\<1 year, mostly fetal-neonatal) LQT1, LQT2, and LQT3 patients. However, whether the LQTS observation is due to the bradycardia or the bradycardia results from the mutations ([@B4], [@B11]) is less clear. Bradycardia-associated mutations in *KCNH2*, so far characterized, result in a decrease in current density, non-functional channels, a shift in voltage of half-activation, and faster deactivation and inactivation rates (Table [S2](#SM1){ref-type="supplementary-material"}).

The above consideration regarding the potential association between sinus bradycardia and the increase in repolarizing I~Ks~ in case of SQT2 similarly holds for the increase in repolarizing I~Kr~ in case of short QT syndrome type 1 (SQT1). Sinus bradycardia is indeed observed in SQT1 patients, although being less common than in SQT2 patients ([@B27]).

LQT3
----

LQT3 is due to gain-of-function mutations in *SCN5A*, the gene encoding the pore-forming α-subunit of the I~Na~ channel (Na~V~1.5). Unlike LQT1 and LQT2, the occurrence of sinus bradycardia is not limited to isolated cases. Several families, including the large Dutch family with the 1795insD founder mutation ([@B28]), show both QT prolongation and sinus bradycardia (Table [1](#T1){ref-type="table"}). A common feature is the increased late current, also named persistent or sustained current, underlying the QT prolongation. Another common feature is the decrease in "window current" due to a positive shift in the steady-state activation curve and/or a negative shift in the steady-state inactivation curve (Table [S3](#SM1){ref-type="supplementary-material"}).

Figures [1A--D](#F1){ref-type="fig"} illustrate the effects of the 1795insD mutation, based on data from recent computer simulations ([@B29]), as set out in the Supplementary Material. The observed increase in cycle length (Figure [1A](#F1){ref-type="fig"}) is largely due to a decrease in net inward current (I~net~) during diastole (Figure [1B](#F1){ref-type="fig"}), which in turn is due to a striking change in the time course of I~Na~ (Figure [1C](#F1){ref-type="fig"}). Where I~Ks~ and I~Kr~ channels are tetramers, the pore of the I~Na~ channel is formed by a single Na~V~1.5 protein. As a consequence, "mutant I~Na~" (Figure [1D](#F1){ref-type="fig"}, dotted red trace) is partly flowing through pure wild-type channels (solid green trace) and partly through pure mutant channels (solid orange trace). There is hardly any current flowing through these mutant channels during diastole due to the decrease in window current. There is, on the other hand, some late current flowing during the AP, albeit with a negligible effect on APD, in contrast to ventricular myocytes, in which the current density of I~Na~ is much larger. These effects are more pronounced during vagal activity (Figures [1E--H](#F1){ref-type="fig"}). The slight decrease in diastolic depolarization rate and increase in cycle length as a result of the inhibition of I~Na~ (Figures [1A,E](#F1){ref-type="fig"}) are in line with experimental observations on isolated rabbit SAN cells ([@B30]).

![Effect of the 1795insD mutation in *SCN5A* on the electrical activity of the Fabbri--Severi model cell of a human SAN pacemaker cell **(A--D)** under control conditions (normal autonomic activity) and **(E--H)** during vagal activity \[based on data from recent computer simulations ([@B29])\]. **(A,E)** Membrane potential (V~m~) of wild-type and mutant cell (solid blue and dotted red trace, respectively). **(B,F)** Associated net membrane current (I~net~). (**C,G**) Associated fast Na^+^ current (I~Na~). **(D,H)** Contribution of wild-type and mutant channels (solid green and orange trace, respectively) to I~Na~ of the mutant cell (dotted red trace).](fcvm-05-00106-g0001){#F1}

The increase in late current ("gain-of-function") is a prerequisite for QT prolongation, but not for sinus bradycardia. A sole decrease in window current ("loss-of-function"), as for example observed in case of the R376C and D1275N mutations in *SCN5A* ([@B31], [@B32]), is sufficient to cause sinus bradycardia.

LQT4
----

Ankyrin-B syndrome, originally named LQT4, is due to heterozygous loss-of-function mutations in *ANK2*, encoding the widely distributed ankyrin-B adaptor protein. Loss of ankyrin-B results in Ca^2+^ homeostasis dysfunction by reduced Na^+^-Ca^2+^ exchange current (I~NCX~), L-type Ca^2+^ current (I~Ca,L~), Na^+^-K^+^-ATPase, and IP3 receptor expression (Table [S4](#SM1){ref-type="supplementary-material"}). Mutations in *ANK2* associated with both QTc prolongation and sinus bradycardia are observed in both large families and single patients (Table [1](#T1){ref-type="table"}).

LQT5
----

LQT5 is due to loss-of-function mutations in *KCNE1*. The encoded protein, named KCNE1 or minK, is a β-subunit that may affect both I~Ks~ and I~Kr~ function. Reports of bradycardia in LQT5 patients are scarce (Table [1](#T1){ref-type="table"}). The observations made to date show reduced I~Ks~ or I~Kr~ density or a shift of I~Ks~ activation to more positive potentials (Table [S5](#SM1){ref-type="supplementary-material"}). Interestingly, the A8V mutation affects I~Ks~ but not I~Kr~, whereas the R98W mutation affects I~Kr~ but not I~Ks~.

LQT6
----

LQT6 is due to loss-of-function mutations in *KCNE2*. The encoded protein, named KCNE2 or MirP1, is a β-subunit that may affect various ion currents. Mutations in *KCNE2* may result in an accelerated inactivation time course of I~Kr~ ([@B33], [@B34]), but also in an increase of I~Ca,L~ ([@B35]), and a reduction of the hyperpolarization-activated current (I~f~) ([@B36]), the latter important for pacemaker activity in human SAN cells ([@B22]). Despite its multiple ion current modulations, *KCNE2* mutations associated with sinus bradycardia are limited to M54T and V65M. In case of the M54T mutation, both I~Kr~ and I~f~ are inhibited (Table [S6](#SM1){ref-type="supplementary-material"}). It is conceivable that the V65M mutation also acts through I~f~, given the well-established effect of KCNE2 on I~f~ ([@B37]).

LQT7
----

Andersen-Tawil syndrome ("LQT7") is a multisystem disorder due to loss-of-function mutations in *KCNJ2*, the gene encoding the Kir2.1 protein, which assembles in tetramers to build the channels that carry the inward rectifier K^+^ current (I~K1~) ([@B38]). Given the low expression of Kir2.1 in human SAN ([@B10]), it is not surprising that HR seems not affected in Andersen-Tawil syndrome patients ([@B39]).

LQT8
----

Timothy syndrome (TS) is a severe multisystem disorder due to gain-of-function mutations in *CACNA1C*, encoding the pore-forming α-subunit of the I~Ca,L~ channel (Ca~V~1.2), and results in bradycardia in almost all patients known, but caused by 2:1 atrioventricular block rather than sinus bradycardia (see footnote to Table [S7](#SM1){ref-type="supplementary-material"}). Although TS is also known as LQT8, because of the extreme QT prolongation in TS patients ([@B40], [@B41]), we restricted the LQT8 data in Table [S7](#SM1){ref-type="supplementary-material"} to non-TS patients. In isolated cases, these show sinus bradycardia (Table [1](#T1){ref-type="table"}). Mutant I~Ca,L~ shows an increase in density or slowing of inactivation (Table [S7](#SM1){ref-type="supplementary-material"}).

LQT9
----

LQT9 is due to mutations in *CAV3*, encoding caveolin-3, an important structural component of caveolae membrane in muscle cells ([@B42]). *CAV3* mutations in heart have been shown to increase the late I~Na~, thus causing QT prolongation as in LQT3 ([@B43], [@B44]). More recently, it has been shown that mutations in *CAV3* may affect several other membrane currents (see footnote to Table [S8](#SM1){ref-type="supplementary-material"}). Sinus bradycardia has been observed in two patients carrying the T78M mutation (Table [1](#T1){ref-type="table"}).

LQT10
-----

LQT10 is due to gain-of-function mutations in *SCN4B*, encoding the Na~V~β4 β-subunit of the I~Na~ channel. A case report exists for an *SCN4B*-L179F mutation with impact on SAN function (Table [1](#T1){ref-type="table"}). In a 21-month-old girl, profound QT prolongation and bradycardia (\<60 bpm) were observed ([@B45]). The *SCN4B*-L179F mutation increases late I~Na~ (Table [S8](#SM1){ref-type="supplementary-material"}) and may thus have effects comparable to LQT3 mutations.

LQT11--LQT16 and beyond
-----------------------

To the best of our knowledge, no sinus bradycardia has been reported in relation to the rare LQTS types LQT11--LQT13 (see footnote to Table [S8](#SM1){ref-type="supplementary-material"}). Genetic variation in *KCNJ3* and *KCNJ5*, encoding the pore-forming Kir3.1 and Kir3.4 ion channel subunits of the acetylcholine-sensitive K^+^ current (I~K,ACh~), and which the latter may underlie LQT13, seems not involved in pathogenesis of SAN dysfunction ([@B46]). However, it is suggested that identification of susceptibility genes for SAN dysfunction requires the construction of a large database of patients and controls whose phenotype should be identified with standard criteria to ensure adequate power for cause-effect studies ([@B47]). Thus, the incidence of some LQTS types may be too low to determine clear associations with bradycardia.

Several reports exist of mutations in the *CALM1--CALM3* genes, each encoding the ubiquitous Ca^2+^ sensing protein calmodulin, in relation to LQTS and sinus bradycardia (Table [1](#T1){ref-type="table"} and Table [S8](#SM1){ref-type="supplementary-material"}). Calmodulin regulates multiple Ca^2+^-related processes in the cardiomyocyte ([@B48]), including, e.g., gating of the I~Ks~ channel ([@B49]). Mutations in *CALM1* and *CALM2* may impair Ca^2+^-dependent inactivation of I~Ca,L~ ([@B50], [@B51]), functionally comparable to the slowed inactivation of I~Ca,L~ in case of LQT8 (Table [S7](#SM1){ref-type="supplementary-material"}).

In Table [1](#T1){ref-type="table"} and Table [S8](#SM1){ref-type="supplementary-material"}, we, like others ([@B52], [@B53]), used LQT14--LQT16 in relation to mutations in *CALM1--CALM3*. We are, however, well aware that the naming LQT16 has been used in other review articles ([@B54], [@B55]) in relation to mutations in *SCN1B* ([@B56]) and in *TRDN* ([@B57]). Altmann et al. identified autosomal recessive homozygous or compound heterozygous mutations in *TRDN*, encoding triadin, associated with LQTS, and themselves proposed that "triadin knockout syndrome" or "*TRDN*-mediated autosomal-recessive LQTS" should be used rather than "LQT17," because of the atypical phenotype that was observed ([@B57]).

Discussion and conclusion {#s3}
=========================

SAN action potentials are generated from a delicate balance of several inwardly and outwardly directed ionic currents, and "Ca^2+^ clock" mechanisms \[for reviews, see ([@B58]--[@B60])\]. While LQTS gene mutations may affect HR by changes in SAN action potential repolarization, it is highly likely that they also affect the intrinsic SAN cycle length by changes in the diastolic, phase 4, depolarization rate, as illustrated by the computer simulations of Figure [1](#F1){ref-type="fig"}.

It is important to realize that a mutation in a single LQTS-related gene may affect several ion currents. This does not only hold for mutations in a Ca^2+^ sensing protein like calmodulin, but also for mutations in the α-subunit of a specific ion channel. The LQT1-related T587M mutation in *KCNQ1* for example does not only reduce I~Ks~, but also fails to increase membrane localization of the *KCNH2*-encoded K~V~11.1 protein, as opposed to wild-type *KCNQ1*, thus also reducing I~Kr~ ([@B61]). Furthermore, we have to keep in mind that the LQTS-induced changes in rhythm may in turn induce changes in expression of specific ion channels, as demonstrated in studies by Tsuji et al. ([@B62]), Yeh et al. ([@B63]), and D\'Souza et al. ([@B64]).

LQT2 and LQT3, but not LQT1, patients have a more pronounced risk for arrhythmias at slower HR ([@B7]). LQT2 and LQT3 gene mutations may therefore increase the risk for cardiac events via a direct effect on HR, as indeed clinically was found in a large family with LQT3 ([@B65], [@B66]). In LQT1 patients, on the other hand, cardiac events tend to occur during exercise ([@B7]). These differences between LQTS types 1--3 underscore the differences in underlying mechanisms and the potential role of sinus bradycardia in cardiac events.

As shown in Tables [S1](#SM1){ref-type="supplementary-material"}--[S8](#SM1){ref-type="supplementary-material"} and summarized in Table [1](#T1){ref-type="table"}, sinus bradycardia has been reported in relation to a large number of LQTS mutations. However, observations are limited to one or a few single patients for most of these mutations (Table [1](#T1){ref-type="table"}). The occurrence of both QT prolongation and sinus bradycardia on a family basis is almost completely limited to LQT3 and Ankyrin-B syndrome ("LQT4"). However, the mechanisms of the associated ventricular arrhythmias and sudden death are largely different. Cardiac events, including nocturnal sudden death, are provoked by the bradycardia and associated excessive QT prolongation in case of LQT3 ([@B65], [@B66]), whereas disturbed calcium homeostasis leads to dysfunction of the SAN cells in case of the Ankyrin-B syndrome, with sudden death occurring after physical exertion and emotional stress ([@B67]--[@B70]).

We conclude that, although sinus bradycardia has been reported in relation to a large number of LQTS mutations, a causative role of this sinus bradycardia in cardiac events is limited to mutations underlying LQTS type 3.
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